Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer ; volume:9 ; number:1 ; day:17 ; month:5 ; year:2019 ; pages:1 ; date:12.2019
Scientific reports ; 9, Heft 1 (17.5.2019), 1, 12.2019

Classification: Soziale Probleme, Sozialdienste, Versicherungen

Creator: Borrero-Palacios, A.
Cebrián, A.
Gómez del Pulgar, M. T.
García-Carbonero, R.
Garcia-Alfonso, P.
Aranda, E.
Elez, E.
López-López, R.
Cervantes, A.
Valladares, M.
Nadal, C.
Viéitez, J. M.
Guillén-Ponce, C.
Rodríguez, J.
Hernández, I.
García, J. L.
Vega-Bravo, R.
Puime-Otin, A.
Martínez-Useros, J.
Del Puerto-Nevado, L.
Rincón, R.
Rodríguez-Remírez, M.
Rojo, F.
García-Foncillas, J.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-019-43809-z

URN: urn:nbn:de:101:1-2019092513234544150893

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Borrero-Palacios, A.
Cebrián, A.
Gómez del Pulgar, M. T.
García-Carbonero, R.
Garcia-Alfonso, P.
Aranda, E.
Elez, E.
López-López, R.
Cervantes, A.
Valladares, M.
Nadal, C.
Viéitez, J. M.
Guillén-Ponce, C.
Rodríguez, J.
Hernández, I.
García, J. L.
Vega-Bravo, R.
Puime-Otin, A.
Martínez-Useros, J.
Del Puerto-Nevado, L.
Rincón, R.
Rodríguez-Remírez, M.
Rojo, F.
García-Foncillas, J.
SpringerLink (Online service)

Other Objects (12)

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab

Target Mutant KRAS with Molecular Glue

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

A pan-KRAS degrader for the treatment of KRAS-mutant cancers

Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Current therapy of KRAS-mutant lung cancer

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression

Correction to: Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab

Target Mutant KRAS with Molecular Glue

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

A pan-KRAS degrader for the treatment of KRAS-mutant cancers

Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Current therapy of KRAS-mutant lung cancer

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression

Correction to: Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab

Target Mutant KRAS with Molecular Glue

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

A pan-KRAS degrader for the treatment of KRAS-mutant cancers

Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Current therapy of KRAS-mutant lung cancer

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression

Correction to: Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab

Target Mutant KRAS with Molecular Glue

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

A pan-KRAS degrader for the treatment of KRAS-mutant cancers

Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Current therapy of KRAS-mutant lung cancer

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression

Correction to: Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab

Target Mutant KRAS with Molecular Glue

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

A pan-KRAS degrader for the treatment of KRAS-mutant cancers

Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Current therapy of KRAS-mutant lung cancer

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression

Correction to: Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab

Target Mutant KRAS with Molecular Glue

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

A pan-KRAS degrader for the treatment of KRAS-mutant cancers

Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Current therapy of KRAS-mutant lung cancer

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression

Correction to: Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index

Related objects

Reset password